We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers
Read MoreHide Full Article
AstraZeneca Plc. (AZN - Free Report) and Merck (MRK - Free Report) announced that their PARP inhibitor, Lynparza (olaparib), was approved by the Japanese Ministry of Health, Labour, and Welfare for the treatment of advanced ovarian, prostate and pancreatic cancers.
Shares of AstraZeneca have increased 1.8% this year so far compared with the industry’s growth of 5.4%.
The first approval as a first-line maintenance treatment in combination with Roche’s (RHHBY - Free Report) Avastin (bevacizumab)for patients with HRD-positive advanced ovarian cancer was based on data from the PAOLA-1 phase III study. In the PAOLA-1 study, HRD-positive ovarian cancer patients had longer median progression-free survival on Lynparza plus Avastin maintenance treatment compared to those on Avastin alone.
The second approval was for the treatment of BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer (mCRPC),which was based on a subgroup analysis of the PROfound phase III study. The study showed that men with BRCA1/2-mutated metastatic castrate-resistant prostate cancer on Lynparza had longer radiographic progression-free survival (PFS) and overall survival than those on Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) or J&J’s Zytiga (abiraterone).
The third approval was for BRCAm metastatic pancreatic cancer based on the results of the POLO phase III study,wherein Lynparza demonstrated a statistically significant and clinically meaningful improvement in PFS versus placebo in patients with germline BRCAm metastatic pancreatic cancer.
Lynparza is presently approved to treat four types of cancers — ovarian, breast, pancreatic and prostate — in certain patient populations in the United States. It is also approved for all or some of these cancers in several other countries.Lynparza is also being evaluated in the earlier-line setting for the approved cancer indications.
The drug generated sales of $1415 million in the first nine months of 2020, reflecting growth of 28% year over year. The drug contributes to growth of the company’s oncology division.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers
AstraZeneca Plc. (AZN - Free Report) and Merck (MRK - Free Report) announced that their PARP inhibitor, Lynparza (olaparib), was approved by the Japanese Ministry of Health, Labour, and Welfare for the treatment of advanced ovarian, prostate and pancreatic cancers.
Shares of AstraZeneca have increased 1.8% this year so far compared with the industry’s growth of 5.4%.
The first approval as a first-line maintenance treatment in combination with Roche’s (RHHBY - Free Report) Avastin (bevacizumab)for patients with HRD-positive advanced ovarian cancer was based on data from the PAOLA-1 phase III study. In the PAOLA-1 study, HRD-positive ovarian cancer patients had longer median progression-free survival on Lynparza plus Avastin maintenance treatment compared to those on Avastin alone.
The second approval was for the treatment of BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer (mCRPC),which was based on a subgroup analysis of the PROfound phase III study. The study showed that men with BRCA1/2-mutated metastatic castrate-resistant prostate cancer on Lynparza had longer radiographic progression-free survival (PFS) and overall survival than those on Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) or J&J’s Zytiga (abiraterone).
The third approval was for BRCAm metastatic pancreatic cancer based on the results of the POLO phase III study,wherein Lynparza demonstrated a statistically significant and clinically meaningful improvement in PFS versus placebo in patients with germline BRCAm metastatic pancreatic cancer.
Lynparza is presently approved to treat four types of cancers — ovarian, breast, pancreatic and prostate — in certain patient populations in the United States. It is also approved for all or some of these cancers in several other countries.Lynparza is also being evaluated in the earlier-line setting for the approved cancer indications.
The drug generated sales of $1415 million in the first nine months of 2020, reflecting growth of 28% year over year. The drug contributes to growth of the company’s oncology division.
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>